just some thoughts from this ann. - as brick has said,...

just some thoughts from this ann.

- as brick has said, management had an extra $29.1m in their bank, but said we have enough for our plans, we'll give it back. not many small caps would have done that. their assessment of future revenue must be pretty confident. imo...

-procurement and installation of test strip production line. will we get government support to make it a full assembly line or saddle up with Ellume with their lateral flow assembly capacity (just randomly slipped into the operon manufacturing ann)? we had $29m if we needed to expand this production line.

-Derek saying "Having the ability to manufacture at scale in- house will provide a great advantage to AnteoTech in speed to market and de-risk manufacturing and the supply chain.”

manufacture at scale means we will be able to produce a significant number. as well, will speed up development of our future tests such as sepsis and covid/flu. being able to manufacture a batch of 400 or so for testing, instead of sending an order to operon, then having to wait for a time when they can fit it into their schedule and then send them back to us, this being repeated if adjustments need to be made, will really speed up predicted timelines.

- extra $4m raised from ssp will be used to accelerate commercialisation of the pipeline of other lateral flow tests and build support for the acceleration of the company's battery development program, including the commercialisation of AnteoX

seeing our annual budget has been pretty close to $4m, the extra funds for staff, equipment and expert advise will be most welcome. for investors, commercialisation of other lateral flow tests and AnteoX will have positive affect on the sp. commercialisation!!!!!

add the above to the operon manufacturing ann
-operon manufacturing 8m complete tests and 20m strips
-applying for MDSAP accreditation
-saliva use case on track for CE mark update in June
-sent readers and tests to a large no. of organisations to validate via an independent trial as a precursor to purchasing
-appointed ground representatives in India and France and have started clinical trials required for individual country marketing authorisation
-1st sale to mining facility in PNG.

it's been a great week for Anteotech imo and has really set us up for many announcements over the coming weeks and all throughout 2021 and beyond. IMO. DYOR, GLTAH etc....